Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Pharma
Roche's high-dose version of Ocrevus flunks phase 3 trial
Roche had high hopes for its high dose version of multiple sclerosis powerhouse Ocrevus, but a trial of the new formulation has come up short.
Kevin Dunleavy
Apr 2, 2025 3:26pm
Merck lays out subcutaneous Keytruda data amid patent brawl
Mar 27, 2025 11:00am
AstraZeneca inks $1.35B deal for subcutaneous cancer drugs
Mar 17, 2025 10:55am
Gilead's PrEP shows early promise in once-yearly dosing
Mar 11, 2025 2:30pm
Merck, Halozyme dig in for patent fight over injectable Keytruda
Mar 6, 2025 11:18am
FDA approves BMS' subcutaneous Opdivo with some limitations
Jan 2, 2025 9:15am
